文献速递基础与转化研究临床试验与 GCP

造血细胞移植供者来源的记忆样NK细胞在白血病患者体内输注后功能性持续存在

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia.
PubMed 文献 · Sci Transl Med · 2022-02-23

该临床试验在15例复发/难治性急性髓系白血病患者中,将同供者记忆样NK细胞联合3周N-803加入减低强度预处理HLA单倍体造血细胞移植。供者记忆样NK细胞耐受良好,87%患者在第+28天达到复合完全缓解,并对应清除TP53变异等高危突变;NK细胞在移植后2个月内为主要血液淋巴细胞,扩增达1104倍,表型与转录分析显示其不同于常规NK细胞且持续超过2个月,体外功能增强。

要点

  • 同供者记忆样NK细胞联合3周N-803支持减低强度预处理HLA单倍体造血细胞移植耐受良好。
  • 15例复发/难治性AML患者中87%在第+28天达到复合完全缓解,对应清除包括TP53变异在内的高危突变。
  • 供者记忆样NK细胞在移植后2个月内为主要血液淋巴细胞,扩增达1104倍,并持续超过2个月。

核心结论

  • 同供者记忆样NK细胞联合3周N-803支持可安全增强减低强度预处理HLA单倍体造血细胞移植用于急性髓系白血病。

研究设计与样本

  • 临床试验(NCT02782546)在15例复发/难治性急性髓系白血病患者中,于减低强度预处理HLA单倍体造血细胞移植第+7天输注同供者记忆样NK细胞并给予3周N-803。

主要发现

  • 15例患者中供者记忆样NK细胞耐受良好,87%患者在第+28天达到复合完全缓解,并对应清除包括TP53变异在内的高危突变。
  • 移植后2个月内NK细胞为主要血液淋巴细胞,扩增达1104倍(历时1至2周)。
  • 表型与转录分析显示供者记忆样NK细胞不同于常规NK细胞,且持续超过2个月。
  • 记忆样NK细胞表达CD16、CD57及高颗粒酶B和穿孔素,并具有独特转录因子谱。
  • 患者体内分化的记忆样NK细胞体外功能较患者和健康供者的常规NK细胞增强。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Natural killer (NK) cells are innate lymphoid cells that eliminate cancer cells, produce cytokines, and are being investigated as a nascent cellular immunotherapy. Impaired NK cell function, expansion, and persistence remain key challenges for optimal clinical translation. One promising strategy to overcome these challenges is cytokine-induced memory-like (ML) differentiation, whereby NK cells acquire enhanced antitumor function after stimulation with interleukin-12 (IL-12), IL-15, and IL-18. Here, reduced-intensity conditioning (RIC) for HLA-haploidentical hematopoietic cell transplantation (HCT) was augmented with same-donor ML NK cells on day +7 and 3 weeks of N-803 (IL-15 superagonist) to treat patients with relapsed/refractory acute myeloid leukemia (AML) in a clinical trial (NCT02782546). In 15 patients, donor ML NK cells were well tolerated, and 87% of patients achieved a composite complete response at day +28, which corresponded with clearing high-risk mutations, including TP53 variants. NK cells were the major blood lymphocytes for 2 months after HCT with 1104-fold expansion (over 1 to 2 weeks). Phenotypic and transcriptional analyses identified donor ML NK cells as distinct from conventional NK cells and showed that ML NK cells persisted for over 2 months. ML NK cells expressed CD16, CD57, and high granzyme B and perforin, along with a unique transcription factor profile. ML NK cells differentiated in patients had enhanced ex vivo function compared to conventional NK cells from both patients and healthy donors. Overall, same-donor ML NK cell therapy with 3 weeks of N-803 support safely augmented RIC haplo-HCT for AML.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Berrien-Elliott MM, Foltz JA, Russler-Germain DA, et al. Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Sci Transl Med. 2022. PMID: 35196021. doi:10.1126/scitranslmed.abm1375

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。